Search Results - "Stoeger, H."

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone by Gnant, M., Filipits, M., Greil, R., Stoeger, H., Rudas, M., Bago-Horvath, Z., Mlineritsch, B., Kwasny, W., Knauer, M., Singer, C., Jakesz, R., Dubsky, P., Fitzal, F., Bartsch, R., Steger, G., Balic, M., Ressler, S., Cowens, J.W., Storhoff, J., Ferree, S., Schaper, C., Liu, S., Fesl, C., Nielsen, T.O.

“…PAM50 is a 50-gene test that is designed to identify intrinsic breast cancer subtypes and generate a Risk of Recurrence (ROR) score. It has been developed to…”
Get full text

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 by Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., Balic, M., Eidtmann, H., Eiermann, W., Steger, G., Kwasny, W., Dubsky, P., Selim, U., Fitzal, F., Hochreiner, G., Wette, V., Sevelda, P., Ploner, F., Bartsch, R., Fesl, C., Greil, R.

“…These final results from ABCSG-12 confirm that twice-yearly ZOL safely enhances the efficacy of adjuvant endocrine therapy. Tamoxifen together with Goserelin…”
Get full text

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype by Gnant, M., Sestak, I., Filipits, M., Dowsett, M., Balic, M., Lopez-Knowles, E., Greil, R., Dubsky, P., Stoeger, H., Rudas, M., Jakesz, R., Ferree, S., Cowens, J.W., Nielsen, T., Schaper, C., Fesl, C., Cuzick, J.

“…In the adjuvant treatment of hormone receptor-positive (HR+) breast cancer, variables like tumour size, grade and nodal status have great impact on therapy…”
Get full text

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24) by Steger, G.G., Greil, R., Lang, A., Rudas, M., Fitzal, F., Mlineritsch, B., Hartmann, B.L., Bartsch, R., Melbinger, E., Hubalek, M., Stoeger, H., Dubsky, P., Ressler, S., Petzer, A.L., Singer, C.F., Muss, C., Jakesz, R., Gampenrieder, S.P., Zielinski, C.C., Fesl, C., Gnant, M.

“…This randomized phase III trial compared pathologic complete response (pCR) rates of early breast cancer (EBC) following neoadjuvant epirubicin–docetaxel (ED)…”
Get full text

Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes by Stöger, H

Get more information

62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer by Gnant, M, Mlineritsch, B, Stoeger, H, Luschin-Ebengreuth, G, Poestlberger, S, Steger, G, Jakesz, R, Singer, C, Eidtmann, H, Greil, R

Get full text

Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial by Heidemann, E., Stoeger, H., Souchon, R., Hirschmann, W.-D., Bodenstein, H., Oberhoff, C., Fischer, J. T., Schulze, M., Clemens, M., Andreesen, R., Mahlke, M., König, M., Scharl, A., Fehnle, K., Kaufmann, M.

“…Background: To determine whether patients with high-risk metastatic breast cancer draw benefit from combination chemotherapy as first-line treatment. Patients…”
Get full text

P286 Preplanned subgroup analysis of ABCSG-12 suggests that benefits of adjuvant zoledronic acid (ZOL) are most pronounced in lowest estrogen environment by Gnant, M, Mlineritsch, B, Stoeger, H, Luschin-Ebengreuth, G, Heck, D, Steger, G, Jakesz, R, Singer, C, Dubsky, P, Greil, R

Get full text

8 Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC) by Steger, G.G, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Rudas, M, Marth, C, Stoeger, H, Singer, C.F, Gnant, M

Get full text

68P Deciphering the interplay between nuclear RNA export factors and long non-coding RNAs in breast cancer metabolism by Klec, C., Schwarzenbacher, D., Gottschalk, B., Margit, R., Prinz, F., Bauernhofer, T., Stoeger, H., Graier, W.F., Pichler, M.

Get full text

P6237Clinical utility of echocardiographic left-ventricular ejection fraction monitoring for cardiotoxicity risk assessment in patients with HER2+ early breast cancer undergoing trastuzumab-based therapy by Posch, F, Glantschnig, T, Firla, S, Smolle, M, Balic, M, Moik, F, Stoeger, H, Zirlik, A, Pichler, M, Rainer, P

“…Abstract Background Monitoring left-ventricular ejection fraction (LVEF) is a routinely-practiced strategy to survey patients with breast cancer (BC) towards…”
Get full text

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial by Gnant, M, Pfeiler, G, Stöger, H, Mlineritsch, B, Fitzal, F, Balic, M, Kwasny, W, Seifert, M, Stierer, M, Dubsky, P, Greil, R, Steger, G, Samonigg, H, Fesl, C, Jakesz, R

“…Background: We investigated whether body mass index (BMI) can be used as a predictive parameter indicating patients who benefit from extended aromatase…”
Get full text

Abstract P6-03-02: Independent evaluation of prognostic value of residual cancer burden (RCB) score on disease free and overall survival of breast cancer patients treated with neoadjuvant systemic treatment at a single institution by Balic, M, Mueller, DH, Hammer, R, Gumpoldsberger, M, Suppan, C, Posch, F, Stoeger, H, Dandachi, N, Prein, K, Hauser, H, Lax, S

“…Abstract Introduction: Among the various approaches to measure response to neoadjuvant chemotherapy in breast cancer patients a significant relationship to…”
Get full text

Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance by Riedl, J., Posch, F., Stotz, M., Bezan, A., Winder, T., Schaberl-Moser, R., Pichler, M., Stoeger, H., Gerger, A.

Get full text

Abstract GS6-04: The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2- breast cancer patients from ABCSG 34 by Dubsky, PC, Fesl, C, Singer, CF, Pfeiler, G, Kronenwett, R, Hubalek, M, Bartsch, R, Stoeger, H, Pichler, A, Petru, E, Bjelic-Radisic, V, Greil, R, Rudas, M, Tea, M-KM, Wette, V, Petzner, AL, Sevelda, P, Egle, D, Fitzal, F, Exner, R, Jakesz, R, Balic, M, Tinchon, C, Bago-Horvath, Z, Lax, S, Regitnig, P, Gnant, M, Filipits, M

“…Abstract Background: In the neoadjuvant treatment setting of ER+/HER2- breast cancer (BC) the choice between preoperative endocrine - (NET) or preoperative…”
Get full text

An elevated fibrinogen/CRP ratio predicts a remarkable survival advantage in patients with metastatic pancreatic cancer by Winder, T., Posch, F., Asamer, E., Stotz, M., Siebenhüner, A., Schlick, K., Magnes, T., Samaras, P., Szkandera, J., Clavien, P.-A., Neureiter, D., Greil, R., Pestalozzi, B.C., Stoeger, H., Gerger, A., Egle, A., Pichler, M.

Get full text

Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival by Gary, T, Belaj, K, Steidl, K, Pichler, M, Eisner, F, Stöger, H, Hafner, F, Froehlich, H, Samonigg, H, Pilger, E, Brodmann, M

“…Background: Asymptomatic venous thrombotic events (VTEs) are possible findings in ambulatory cancer patients. Data regarding the incidence and clinical impact…”
Get full text

Long-term cardiovascular complications in stage I seminoma patients by Terbuch, A., Posch, F., Annerer, L. M., Bauernhofer, T., Pichler, M., Szkandera, J., Hutterer, G. C., Pummer, K., Partl, R., Kapp, K. S., Stöger, H., Gerger, A., Stotz, M.

“…Purpose The cure rate of stage I seminoma patients is close to 100% and so the recent focus of clinical research has shifted onto the prevention of…”
Get full text

Abstract P6-10-01: Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34) by Singer, CF, Pfeiler, G, Hubalek, M, Bartsch, R, Stoeger, H, Pichler, A, Petru, E, Greil, R, Rudas, M, Tea, M-KM, Wette, V, Petzer, AL, Sevelda, P, Egle, D, Dubsky, PC, Balic, M, Tinchon, C, Bago-Horvath, Z, Frantal, S, Michael, G

“…Abstract Background: Immune-based therapeutic strategies represent a promising approach in early and advanced breast cancer treatment. MUC1 glycoprotein is…”
Get full text

Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy by Mollnar, S., Pondorfer, P., Kasparek, A.-K., Reinisch, S., Moik, F., Stotz, M., Halm, M., Szkandera, J., Terbuch, A., Eisner, F., Gerger, A., Kapp, K. S., Partl, R., Vasicek, S., Weiland, T., Pichler, M., Stöger, H., Thurnher, D., Posch, F.

“…Purpose Radiochemotherapy (RCT) is an effective standard therapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Nonetheless, toxicity…”
Get full text